Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases.

LEO Pharma A/S; FINANCIAL planners; STAT proteins; ROYALTIES (Patents); SMALL molecules; BUSINESS partnerships; GILEAD Sciences Inc.

Gilead Sciences and LEO Pharma have entered into a strategic partnership to focus on developing treatments for inflammatory diseases. Gilead will have global rights to develop and commercialize the oral STAT6 program, with LEO Pharma eligible to receive up to $1.7 billion in payments. The agreement also includes potential royalties for both companies on sales of oral and topical STAT6 products. This partnership is expected to impact Gilead's 2025 earnings per share, with Bank of America Securities serving as financial advisers to LEO Pharma in the transaction. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)